Events

MSCA Doctoral Networks 2024 call - COM & REA information event
JUN
Fri
07
09:30 - 12:30

This was 1 year ago

Location

virtual

Programmes
MSCA MSCA

The European Research Executive Agency (REA) and the Directorate-General for Education, Youth, Sport and Culture (DG EAC) of the European Commission organize an online information event on Marie Sklodowska-Curie Actions (MSCA) Doctoral Networks (DN) 2024 call. This event aims at informing potential applicants and stakeholders about the MSCA DN 2024 call.

The participants will have the opportunity to raise their questions through Slido, in advance of the event (as of 30 May 2024) and during the Q&A session at the end of the event.

Programme in brief

  • 09.30-09.45 Opening remarks and welcome address
  • 09.45-11.00 
    • Introduction of the session
    • Presentation DG EAC on policy priorities
    • Presentation REA on DN 2024 call – novelties and Industrial Doctorate/Joint Doctorate incentives
  • 11.15-12.15 Questions & Answers
  • 12.15-12.30 Closing remarks

All information related to the online info day is available on the European Commission research and innovation community platform

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.